United States, Institutional
Change
Showing
of
Insights Posts
Go-to-market strategy: 5 lessons learned
Our Value Creation Team explores go-to-market strategy best practices, highlighting stages of growth, product-market fit, the science of sales, and much more.
4
min
Article
2026-06-30
Climate venture capital: Innovation versus hype
Greg Wasserman, Head of Private Climate Investing, discusses the balance between innovation and hype in climate venture capital. He explores automation in agriculture and manufacturing as well as the emerging commercial applications of generative AI.
3
min
Video
2026-06-30
Innovation in late-stage private markets
Matt Witheiler, head of Late-stage Growth, explores innovation and hype in late-stage private markets, discussing AI and defense technology.
3
min
Video
2026-06-30
Early-stage venture: Innovation versus hype
Wellington Access Ventures' Jackson Cummings discusses promising innovations in edge AI and embedded fintech. In addition, he highlights the potential hype surrounding consumer AI and quantum computing.
3
min
Video
2026-06-30
Private biotech innovation versus hype
Nilesh Kumar discusses the next generation of biotech disruptors in obesity, autoimmunity, and oncology, focusing on drugs that solve real-world unmet medical needs.
3
min
Video
2026-06-30
Preparing to go public: Five IPO lessons learned
Our Value Creation Team highlights five IPO preparation lessons learned for private companies aiming for successful public market entry.
3
min
Article
2026-05-31
Sizing private-market allocations
Our multi-asset experts explore three key components of sizing private market allocations, offering a framework to evaluate the capacity to take on illiquidity, the need for excess return, and the ability to consistently source 'good' investments.
8
min
Article
2026-05-31
SeatGeek deal overview
Head of Late-stage Growth Matt Witheiler and Equity Research Analyst Peter Blain highlight their insights on Wellington’s investment in SeatGeek, discussing the company's potential in primary and secondary ticketing in the growing ticketing landscape.
7
min
Video
2026-04-30
Private biotech market update: IPOs, M&A, and innovation
Our biotech venture capital experts explore the state of the private biotech market, highlighting the potential IPO-market rebound, surge in private M&A, and the focus on clinical-stage opportunities.
6
min
Article
2026-04-30
Databricks deal overview
Head of Late-stage Growth Matt Witheiler and Global Industry Analyst James McNay discuss their work together on Wellington’s investment in Databricks, highlighting the company’s innovation in AI and data analytics amid the evolving tech landscape.
6
min
Video
2026-05-01
Private market update
Check out our collection of videos on the state of the venture capital and private credit markets, featuring leaders from across our private investing platform.
Video
2026-04-30
Early-stage venture: Deployment, valuations, exits
Head of Wellington Access Ventures Jackson Cummings discusses his latest views on early-stage venture capital and why he’s “cautiously optimistic” on deployments, valuations, and exits.
3
min
Video
2026-03-31
Late-stage growth investing: Deployment, valuations, and exits
Matt Witheiler, head of late-stage growth, outlines the state of the late-stage private market, discussing deployments, valuations, and exits.
7
min
Video
2026-03-31
Climate venture capital: Deployment, valuations, exits
Greg Wasserman, head of private climate investing, explores today’s normalizing valuations, encouraging IPO and M&A trends, and potentially actionable opportunities in climate venture capital.
2
min
Video
2026-03-31
Private biotech investing in 2025
Nilesh Kumar, head of biotech private investing, shares his outlook for 2025, weighing headline risk against biotech venture capital's potential tailwinds.
4
min
Video
2026-02-28
Private climate investing in 2025
Greg Wasserman, head of private climate investing, explores the nuanced impact of the Trump administration on climate venture capital, discussing the Inflation Reduction Act, automation, and climate adaptation opportunities.
3
min
Video
2026-02-28
Late-stage growth investing in 2025
How could Trump 2.0 impact late-stage private companies? Matt Witheiler, head of late-stage growth, explores the potential impact of inflation and tariffs on the late-stage market in 2025.
2
min
Video
2026-02-28
Venture capital in 2025: Deployment and valuations
How are valuation and deployment trends shaping today’s opportunities in venture capital? Our VC experts explore the current state of the market and their expectations for 2025.
4
min
Video
2026-02-28
Early-stage venture in 2025
Jackson Cummings, head of Wellington Access Ventures, explores the potential impacts of Trump 2.0 on early-stage venture, highlighting deregulation, fintech opportunities, AI-driven manufacturing innovations, and more.
3
min
Video
2026-02-28
No more free lunch: Impact of higher interest rates on private equity
We explain what the direct and indirect rate exposure of buyouts, venture capital, growth equity, secondaries, and fund-of-funds mean for investors.
5
min
Article
2026-02-28
WellSaid: Partnering with climate founders
Wellington head of private climate Greg Wasserman discusses his team's approach to helping private companies progress along their growth journey
Video
2026-02-28
The role of public/private collaboration
Josh Sommerfeld, health care sector lead for late-stage private investments, highlights why he believes working with public-market colleagues like Dave Khtikian helps him be better at the four key parts of his job: sourcing, diligence, pricing, and exiting.
2
min
Video
2026-01-31
Venture capital roundtable: 2025 outlook
In this roundtable, we explore the short- and longer-term implications of Trump 2.0, share our views on the IPO and M&A environments, and dive into the potential impact of tariffs, labor scarcity, and a higher-for-longer interest-rate environment.
18
min
Video
2026-01-31
Private market perspectives
Hear from private market experts across our early-stage venture, climate growth, late-stage biomedical, late-stage growth, private credit, and ESG teams.
5
min
Video
2026-01-28
Private biotech: Immunology and inflammation’s third wave
Our experts discuss how I&I is building on industry progress to offer new treatment solutions and interesting opportunities for private biotech investors.
5
min
Article
2025-12-01
Venture capital outlook for 2025: 5 key trends
Our venture capital experts are encouraged by the healthier environment for venture capital in 2025. In this year's outlook, they explore key themes for the year ahead, including: higher deployment, AI, rebounding IPOs, and impacts of the 2024 election.
7
min
Article
2025-12-31
Private Investment Outlook
In our private market outlook collection, we explore the themes driving the rapid evolution of private credit and private equity markets.
Article
2025-12-31
AI is hungry: What’s on the menu?
Our technology venture capital experts explore AI’s potential for disruption, highlight potential winners and losers, and dive deep into the innovation’s impact on the software industry.
9
min
Article
2025-11-30
Measuring impact in venture capital
We highlight why venture capital matters to impact investors and how to authentically measure and manage impact in this asset class.
5
min
Article
2025-11-01
Decoding impact expectations: best practices for impact investors and companies
We share three recommendations each for impact investors and companies to help them better understand and manage each other's expectations.
6
min
Article
2025-10-31
Designing an executive compensation program: Five best practices for private companies
Our Value Creation Team highlights best practices for creating effective executive compensation programs for private companies approaching IPO.
6
min
Article
2025-10-31
Private equity deep dive
We explore four key private equity questions to help investors better understand how these strategies compare and complement each other in a portfolio. In particular, we highlight the distinct opportunity sets, risk-return characteristics, and portfolio roles of venture capital and buyout strategies.
5
min
Article
2025-09-30
Biotech IPOs in 2025: Quantity, quality, and best practices
We explore today's biotech IPO market, highlighting recent market trends, key characteristics for successful biotech IPOs, and best practices to sustain momentum as a public biotechnology company.
4
min
Article
2025-08-31
Asia’s evolving venture capital market
What's next for Asian venture capital? After a decade of growth, we explore key questions and best practices for VC investors and private companies in the region.
6
min
Article
2025-08-31
AI governance for private companies
Explore the critical need for AI governance for private companies, addressing evolving risks, regulations, and best practices for responsible gen AI usage.
8
min
Article
2025-07-30
Disappearing unicorns: The importance of capital efficiency in a higher-for-longer rate environment
Members of our late-state growth equity team share their views on the impact of interest rates on venture capital activity — including the ability of companies to reach “unicorns” status.
8
min
Whitepaper
2025-07-31
8 emerging venture capital trends
We share eight of the themes driving venture capital markets in 2024, including capital efficiency, DPI, the IPO market recovery, and much more.
7
min
Article
2025-06-30
Built to last? Identifying durable health care start-ups
Two members of our late-stage growth team share insights and results from their recent analysis of enterprise-value trajectories for private, non-biotech health care companies.
14
min
Article
2025-05-23
Hyper-personalization and the AI-driven commerce revolution
A member of our early-stage venture team explores the many ways in which artificial intelligence is likely to transform the consumer experience.
Article
2025-03-31
Venture capital outlook: Signals point to a brighter 2024
Our private investing team sees positive signals indicating that the recent downturn in venture capital may have hit bottom. Just as privates trailed the public market correction in 2022, we believe they will follow its recovery.
Article
2025-01-31
Five key ESG topics for private companies in 2024
See where our ESG for Private Investments team is focusing to minimize investment risk and maximize company value in 2024 and beyond.
Article
2024-12-31
Growth efficiency: The new venture capital regime
Frederik Groce, Deal Lead for Wellington Access Ventures, explores how the 'growth-at-any-cost' venture capital regime has shifted to a focus on growth efficiency, highlighting two key metrics for companies to keep top of mind.
Article
2024-11-30
Private investing portfolio company interview with AMP Robotics CEO
Dr. Matanya Horowitz, CEO of AMP Robotics, highlights how the company integrates AI and robotics into the recycling industry and explores the “actionable guidance” Wellington provides on ESG and other strategic issues.
Video
2024-10-31
Supporting the next generation of entrepreneurs
We highlight how Wellington Access Ventures, our early-stage VC platform, partners with historically underrepresented founders and offers the capital, resources, and networks that these companies have historically lacked.
Article
2024-10-24
Private investing portfolio company interview with RayzeBio CEO Ken Song
Dr. Ken Song, President and CEO of RayzeBio, discusses the company’s innovative approach to radiopharmaceuticals and highlights how Wellington’s public and private investment expertise is distinctive in the health care space.
Video
2024-09-30
WellSaid: Partnering with portfolio companies
Co-head of private investing Michael Carmen explores how we partner with portfolio companies to help them along the "last mile from the private market to the public market" including on key ESG issues for private companies to consider.
Podcast
2024-07-24
The critical role of ESG for private companies
Explore our full ESG insights for private companies series with our latest research on governance, DEI, climate, and much more.
Article
2024-10-31
URL References
Related Insights